Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

USAID and Takeda launch dengue prevention campaign

Campaign launched to spread awareness regarding dengue prevention and control

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT

Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation

This transaction is the third acquisition by three different Japanese players in this segment

Elucid appoints Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media

Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial

Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension

Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets

This product will be manufactured at Lupin’s Pithampur facility in India